Our finding that FIH loss alone can boost anti-tumour immunotherapy is in agreement with our own prior work on overexpression of HIF1 and HIF2 isoforms with differential sensitivity to FIH and VHL control (9). This evidence concerns the gene VHL and neoplasm.